Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update
I'm PortAI, I can summarize articles.
Boston Scientific has agreed to acquire Penumbra for approximately $15 billion in cash and stock, enhancing its cardiovascular portfolio. The deal values Penumbra at $374 per share, a 19% premium over its previous closing price. Shareholders can choose between cash or Boston Scientific shares. The acquisition is expected to close later this year, with Boston Scientific financing the cash portion through existing cash and new debt. The deal aims to expand into new vascular segments, and Penumbra's CEO will join Boston Scientific's board.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments